A. Branch RVO (BRVO) occurs more frequently than central RVO (CRVO) B. Most patients will experience RVO is both eyes simultaneously C. Patients with CRVO in one eye are more likely to develop an occlusion in the fellow eye compared with those with BRVO D. RVO is the most common cause of vision loss in the United States E. Unsure

A. Increasing age B. Diabetes mellitus C. Hypertension D. Use of any oral contraceptives E. Unsure

A. Severe eye pain B. White or yellow discharge C. Decreased visual acuity in one eye D. Sudden onset photophobia E. Unsure

A. Branch RVO B. Central RVO C. Hemiretinal RVO D. Both branch and central RVO E. Unsure

A. The patient's prognosis is likely better than if he presented with branch retinal vein occlusion (BRVO) B. Treatment with an intravitreal corticosteroid would reverse the occlusion C. Early treatment would be the most appropriate strategy for this patient D. The patient is less likely to develop neovascularization than if he presented with BRVO E. Unsure

A. Hypertension B. Cataracts C. Endophthalmitis D. Retinal vein detachment E. Unsure

A. A patient with a financial barrier to receiving care B. A patient with elevated intraocular pressure C. A patient who is unwilling to receive monthly injections D. A patient with retinal vein occlusion without macular edema E. Unsure

A. Aflibercept B. Bevacizumab C. Ranibizumab D. Dexamethasone intravitreal implant E. Unsure

A. Local adverse events are significantly more common with ranibizumab compared to aflibercept B. Local adverse events are significantly more common with aflibercept compared to bevacizumab C. Local adverse events are significantly more common with bevacizumab compared to ranibizumab D. Local adverse event rates are similar between aflibercept, bevacizumab, and ranibizumab E. Unsure

A. Bevacizumab B. Aflibercept C. Dexamethasone D. No treatment E. Unsure